Alectinib in Crizotinib Refractory ALK Rearranged Non Small Cell Lung Cancer: A Phase II Global Study.
PURPOSE Crizotinib confers improved progression free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK) rearranged non small cell lung cancer (NSCLC) but progression invariably occurs. We investigated the efficacy and safety of alectinib, a potent and selective ALK inhibitor with excellent CNS penetration, in patients with crizotinib refractory ALK positive NSCLC. PATIENTS AND METHODS Alectinib 600 mg was administered orally twice daily. The primary end point was objective response rate (ORR) by central independent review committee (IRC) RESULTS Of the 138 patients treated, 84 patients (61% had CNS metastases at baseline, and 122 were response evaluable (RE) by IRC. ORR by IRC was 50% (95% CI, 41% to 59% and the median duration of response (DOR) was 11.2 months (95% CI, 9.6 months to not reached) In 96 patients (79% previously treated with chemotherapy, the ORR was 45% (95% CI, 35% to 55% Median IRC assessed progression free survival for all 138 patients was 8.9 months (95% CI, 5.6 to 11.3 months) CNS disease control rate was 83% (95% CI, 74% to 91% and the median CNS DOR was 10.3 months (95% CI, 7.6 to 11.2 months) CNS ORR in 35 patients with baseline measurable CNS lesions was 57% (95% CI, 39% to 74% Of the 23 patients with baseline CNS metastases (measurable or nonmeasurable) and no prior radiation, 10 (43% had a complete CNS response. At 12 months, the cumulative CNS progression rate (24.8% was lower than the cumulative non CNS progression rate (33.2% for all patients. Common adverse events were constipation (33% fatigue (26% and peripheral edema (25% most were grade 1 to 2. CONCLUSION Alectinib is highly active and well tolerated in patients with advanced, crizotinib refractory ALK positive NSCLC, including those with CNS metastases.
Journal of clinical oncology official journal of the American Society of Clinical Oncology